Highlights CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			Pre-market 08:21:34 am
2.04 ^USD	-51.31%		2.06	+0.98%

May. 09	BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating	MT
May. 09	Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M	May. 08	MT
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)	May. 08	CI
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)	May. 07	CI
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors	Apr. 08	CI
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	Mar. 18	CI
Stocks to Watch : Oracle, Mission Produce, CytomX Therapeutics	Mar. 11	DJ
CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate	Mar. 11	DJ
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q4 Revenue $26.6M, vs. Street Est of $21.2M	Mar. 11	MT
CytomX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b	Jan. 24	CI
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q3 Revenue $26.4M, vs. Street Est of $13.4M	Nov. 07	MT
CytomX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference	23-10-18	CI
CytomX Therapeutics, Inc. Enters into a Transition Agreement with AbbVie Global Enterprises Ltd	23-08-24	CI
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q2 Revenue $24.7M, vs. Street Est of $13.7M	23-08-08	MT
CytomX Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
CYTOMX THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-27	AQ
CytomX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Highlights

Filters